Drug intelligence / Profile preview

AG-3132

Development stage: Preclinical
Lead developer: Angarus Therapeutics
Modality: Small Molecules

Overview

AG-3132 is a small molecule inhibitor targeting ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1). It is being developed by Angarus Therapeutics for the treatment of neoplasms, with its primary mechanism of action as an ENPP1 inhibitor. The drug aims to modulate immune regulatory mechanisms within the tumor microenvironment, potentially enhancing anti-tumor immunity. As of the latest update, AG-3132 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1][3].

Targets

ENPP1

Beyond the preview

Go deeper on AG-3132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-3132.

Explore the full profile